

Forschungsprojekte

Projets de recherche

Unterstützt von:

Krebsliga Schweiz, Oncosuisse

Soutenus par:

Ligue suisse contre le cancer, Oncosuisse

2004

Projektverantwortliche/r Institut	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Responsable de la recherche Institut	Numero du projet Titre du projet	Durée (mois)	Montant (CHF)
Aebi Stefan , PD Dr. med. Universität Bern Inselspital 3010 Bern	OCS 01534-03-2004 Assessment of the effect of a Nurse Specialist service for Breast and Gynaecological Cancer Care in a Swiss Hospital	24	181'000
Ammann Roland A. , Dr. med. Pediatric Hematology/ Oncology Children's University Hospital Inselspital 3010 Bern	OCS 01466-02-2004 A prospective multi-center study on pediatric patients with fever in severe chemotherapy induced neutropenia. Including a randomized comparison of outpatient management and oral antimicrobial therapy versus inpatient management and intravenous antimicrobial therapy in a subgroup with low risk of adverse events (low-risk subgroup study) Swiss Pediatric Oncology Group/ SPOG 2003 FN.	36	96'600
Arcaro Alexandre , Dr. University of Zürich Division of Clinical Chemistry and Biochemistry 8032 Zürich	OCS 01501-02-2004 Signalling by specific phosphoinositide 3- kinase isoforms in human glioblastoma and neuroblastoma cell proliferation, chemoresistance and metastasis	36	167'800
Beard Peter , Dr phil Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	OCS 01576-08-2004 Virus-mediated killing of cancer cells that lack functional p53: an approach to targeting the genetic instability of tumours	24	194'500
Beck Popovic Maja , Dr CHUV 1011 Lausanne	AND OCS 01545-06-2004 Financement de anti-GD2 pour l'étude européenne HR-NBL-1/ESIOP	72	30'000
Beermann Friedrich , Dr Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	OCS 01500-02-2004 In vivo screening of candidate genes in melanoma	36	243'800

Bertoni Francesco , Dr. Oncology Institute Southern Switzerland 6500 Bellinzona	OCS 01517-02-2004 Cancer genes involved in genetic progression of germinal centre B cell lymphomas	24	166'900
Carbone Giuseppina , Dr. med. IOSI - Lab of Experimental Oncology 6500 Bellinzona	OCS 01513-02-2004 Ets-domain transcription factors in prostate cancer	24	174'600
Cerny Andreas , Prof. Dr. med. Ospedale Regionale di Lugano Sede Civico 6903 Lugano	OCS 01479-02-2004 Preclinical development of liposomally formulated antivirally active small interfering RNA's (Liforna's) against Hepatitis C Virus as a novel strategy to combat hepatocellular carcinoma	12	106'400
Citi Sandra Department of Molecular Biology University of Geneva 1211 Genève 4	OCS 01390-08-2003 The role of the tight junction protein cingulin in epithelial morphogenesis and differentiation.	36	281'700
Dobbelaere Dirk A.E. , Prof. Dr. Institut für Tierpathologie Molekulare Pathologie Universität Bern 3012 Bern	OCS 01414-08-2003 A novel role for IKK in centrosome function and cell cycle progression	36	170'300
Donda Alena , Dr Biochemistry Institute University Lausanne 1066 Epalinges	OCS 01407-08-2003 Antibody-CD1d bifunctional molecules for targeting innate immunity to cancer cells	24	117'700
Dubey Raghvendra , Dr. University Hospital Zürich 8091 Zürich	OCS 01551-08-2004 Pathophysiological role of estrogen metabolism in breast cancer	38	258'300
Frei Christian , Dr. Zoologisches Institut 11-J-26 University of Zurich 8057 Zürich	OCS 01575-08-2004 The function of Drosophila hypoxia-inducible factor (Hif-1) and its transcriptinal targets in cellular growth control	36	167'000
Frese Steffen , Dr. Department of Clinical Research Laboratory of General Thoracic Surgery 3010 Bern	OCS 01508-02-2004 PG490 (triptolide)-mediated sensitization of non-small cell lung cancer cells to Apo2L/TRAIL-induced apoptosis - in vivo investigation in two different lung cancer mouse models with established tumors	24	205'300
Gönczy Pierre , Dr phil Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	OCS 01495-02-2004 Cellular and molecular dissection of centrosome duplication in C. elegans: from model organism towards therapeutic opportunities	36	291'800
Grapin-Botton Anne , Dr Institut Suisse de Recherches Expérimentales sur le Cancer ISREC, Pancreas Developmental Biology group 1066 Epalinges	OCS 01396-08-2003 Mesenchyme invasion by the pancreas epithelium during normal development: understanding pancreas adenocarcinoma invasivity and metastasis	24	218'800
Gratwohl Alois , Prof. Dr. med. Kantonsspital Basel Bereich Innere Medizin I 4031 Basel	KLS 01520-02-2004 Predicting transplant rates in haematopoetic stem cell transplantation	36	193'100
Greber Urs , Prof. Zoologisches Institut Universität Zürich 8057 Zürich	OCS 01570-08-2004 The entry of oncolytic species B Adenovirus serotypes into cancer cells	15	72'800

Gutzwiller Felix , Prof. Dr. med. Institute of Social and Preventive Medicine University of Zurich 8006 Zürich	OCS 01484-02-2004 Medical end-of-life decision-making among Swiss physicians with regard to cancer patients with particular consideration of the types of organisation	36	120'300
Hajnal Alex , Dr. phil. Zoologisches Institut Universität Irchel 8057 Zürich	KLS 01504-02-2004 Notch signaling during Caenorhabditis elegans development	36	271'500
Hamel Christian , Dr. med. Kantonsspital Basel 4031 Basel	OCS 01579-08-2004 Clinical function after total mesorectal excision and rectal replacement. A prospective randomized trial comparing side to end anastomosis, Colon-J-Pouch and straight coloanal anastomosis. A project of the SAKK (Swiss Group for Clinical Cancer Research)	36	303'300
Heim Markus Hermann , Prof. Kantonsspital Basel 4031 Basel	OCS 01475-02-2004 Prevention of hepatitis C virus associated hepatocellular carcinoma by interferon treatment of chronic hepatitis C: the role of virus induced interferon resistance	24	168'800
Hirth Frank , Dr. Institute of Zoology University of Basel 4056 Basel	OCS 01561-08-2004 The role of Brat/TRIM3 in fly and human brain tumor formation	24	209'200
Hitz Felicitas , Dr. Kantonsspital St. Gallen 9007 St. Gallen	OCS 01387-08-2003 Gemcitabine for the treatment of patients with newly diagnosed, relapsed or therapy resistant mantle cell lymphoma - a multicenter phase II trial of the SAKK (Swiss Group for Clinical Cancer Research).	12	62'100
Hoessli Daniel C. , Prof Département de Pathologie Centre médical universitaire 1211 Genève 4	OCS 01408-08-2003 Signaling adaptors in lymphoma cell rafts: potential targets for therapeutic intervention	24	212'000
Huard Bertrand , Ph. centre medical universitaire 1211 Genève 4	OCS 01391-08-2003 Use of a spontaneous tumor model to study T cell tolerance to melanoma antigens and test vaccination strategies	36	156'500
Iggo Richard , Dr Institut Suisse de Recherches Expérimentales sur le Cancer ISREC, Oncogene Group 1066 Epalinges	OCS 01482-02-2004 Microarray analysis of breast cancer in the context of a prospective neoadjuvant clinical trial	24	116'700
Karch François , Dr phil Dépt. de Zoologie et Biologie animale 1211 Genève 4	OCS 01399-08-2003 Function of chromatin assembly factor ASF1 in cell cycle control	24	176'500
Kiss Alexander , Prof. Kantonsspital Basel 4031 Basel	OCS 01519-02-2004 End of life and death in human stem cell transplantation (HSCT): a qualitative study in doctors, nurses and bereaved families	24	197'100
Kroschewski Ruth , Dr. rer. nat. ETH-Hoenggerberg Institute of Biochemistry 8093 Zürich	OCS 01507-02-2004 Analysis of Noey2, an unconventional Raf inhibitor	24	124'000

Leibundgut Kurt , PD Dr. med. Universitäts-Kinderklinik G7/529 Inselspital 3010 Bern	OCS 01470-02-2004 Platelet transfusion of single donor apheresis products in pediatric oncology: Is there a role for ABO matching?	18	54'700
Levi Fabio , Prof. Dr méd Registre vaudois des tumeurs Institut universitaire de médecine sociale et préventive / CHUV 1011 Lausanne	OCS 01467-02-2004 Monitoring and investigation of cancer mortality in Europe	36	270'000
Locher Kaspar , Prof. Institut für Molekularbiologie und Biophysik ETH Hönggerberg 8093 Zürich	OCS 01558-08-2004 Mechanistic and structural investigation of human ABC transporters causing multi-drug resistance in cancer cells	36	169'900
Lutz Jean-Michel , Dr med Registre Genevois des tumeurs 1205 Genève	KLS 01499-02-2004 Cancer survival in Europe, North America, Australia and Japan: the CONCORD study Participation of the Swiss Cancer registries network in the second phase "high resolution"	24	98'000
Mamot Christoph , Dr. med. University Hospital Basel 4031 Basel	OCS 01577-08-2004 Use of anti-EGFR immunoliposomes to overcome drug resistance mechanisms in human cancer	30	193'000
Martinou Jean-Claude , Prof University of Geneva 1211 Genève	OCS 01580-08-2004 Preventing mitochondrial fission: an approach to block cell division and to decrease tumor growth	36	165'800
McKee Thomas , Dr Institut Universitaire de Pathologie 1011 Lausanne	OCS 01494-02-2004 Generation of B cell lymphomas in mice using a novel herpesvirus vector	12	99'300
Michielin Olivier Swiss Institute of Bioinformatics 1066 Epalinges	OCS 01381-08-2003 Rational optimization of peptide vaccines for immunotherapy of cancer	36	134'600
Neuenschwander Hans , Dr. IOSI Ospedale Italiano 6962 Viganello	OCS 01533-03-2004 A randomised, controlled, double-blind study on the effects of morphine (0.5 % gel) applied topically in patients with painful skin ulcers	24	40'000
Odermatt Alex , Dr. Dep. für Klinische Forschung Inselspital, Kinderklinik, G4-815 3010 Bern	OCS 01402-08-2003 A Novel Strategy for Controlling Steroid Hormone-Dependent Tumors	24	211'700
Orend Gertraud , Dr. rer. nat. Universität Basel Biochemisches Institut 4051 Basel	OCS 01419-08-2003 Role of tenascin-C, syndecan-1 and integrin avb3 on the inhibition of tumor cell adhesion to fibronectin	24	203'700
Pruschy Martin , Dr. Universitätsspital Klinik für Radio-Onkologie 8091 Zürich	OCS 01514-02-2004 Ionizing Radiation and Inhibition of Angiogenesis: Influence of the Tumormilieu for this Combined Treatment Modality	24	191'200
Radtke Freddy , Dr Ludwig Institute for Cancer Research (LICR) 1066 Epalinges	OCS 01560-08-2004 The role of Notch2 in murine epidermis	36	140'600
Romero Pedro , Dr méd Ludwig Institute for Cancer Research Hôpital Orthopédique 1005 Lausanne	OCS 01596-08-2004 Toll like receptor 3 ligands as multifunctional adjuvants for cancer immunotherapy	24	192'700

Rüegg Curzio , Prof Dr med Centre Pluridisciplinaire d'Oncologie UNIL and ISREC 1066 Epalinges	OCS 01485-02-2004 Integrin-mediated endothelial cell death: dissection of molecular mechanisms and design of improved Arg-Gly-Asp based therapeutics	36	228'200
Ruiz i Altaba Ariel , Prof. Faculty of Medicine 1211 Genève	OCS 01584-08-2004 Role of GLI gene function in brain tumors	36	312'400
Schäfer Werner Beat , PD Dr. phil II Universitäts-Kinderklinik 8032 Zürich	KLS 01473-02-2004 Beyond gene expression profiling: Characterization of novel diagnostic markers and therapeutic targets in pediatric sarcomas	24	193'500
Schärer Orlando , Dr. Institut für Molekulare Krebsforschung Universität Zürich 8008 Zürich	OCS 01413-08-2003 DNA interstrand crosslink repair in mammals	36	334'100
Simanis Viesturs , Dr phil Institut Suisse de Recherches Expérimentales sur le Cancer ISREC Cell Cycle Control Laboratory 1066 Epalinges	OCS 01383-08-2003 Analysis of the role of centriolin in regulating cytokinesis	24	218'800
Singer Gad , Dr. Institute of Pathology University of Basel 4031 Basel	OCS 01506-02-2004 Identification of drug resistance genes in ovarian carcinoma	24	168'800
Skoda Radek C. , Prof. Kantonsspital Basel 4031 Basel	OCS 01411-08-2003 The Pathogenesis of Myeloproliferative Disorders	24	203'700
Stahel Rolf Arno , Prof. Dr. med. Klinik und Poliklinik für Onkologie Universitätsspital Zürich 8044 Zürich	OCS 01491-02-2004 Expression profiling in malignant pleural mesothelioma patients undergoing neoadjuvant chemotherapy	24	80'400
Stiefel Frédéric , PD Dr med Service de Psychiatrie de Liaison - CHUV 1011 Lausanne	OCS 01585-08-2004 Development of an adequate method to assess meaning in life of cancer patients with advanced disease	12	53'900
Stiefel Frédéric , PD Dr med Service de Psychiatrie de Liaison - CHUV 1011 Lausanne	OCS 01595-08-2004 Effects of Communication Skills Training on oncology clinicians' communication styles and defense mechanisms	14	163'600
Tamm Michael , Prof. Kantonsspital Basel 4031 Basel	KLS 01518-02-2004 Optimizing care in patients with newly diagnosed bronchial carcinoma: Evaluation of their needs and of a patient centered intervention	36	281'000
Taverna Christian , Dr. Klinik und Poliklinik für Onkologie Universitätsspital 8091 Zürich	OCS 01468-02-2004 Comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma: A randomized phase III trial of the SAKK (Swiss Group for Clinical Cancer Research)	36	190'400
Thome-Miazza Margot , Dr Institut de Biochimie Université de Lausanne 1066 Epalinges	OCS 01379-08-2003 The role of Bcl-10 and MALT1 in lymphocyte activation and lymphoma formation	36	171'300

Trueb Beat , Prof. ITI Research Institute University of Berne 3010 Bern	OCS 01463-02-2004 Role of a novel FGF receptor in the formation of tumors	36	173'400
Vorbuerger Stephan , Dr. med. Department of Visceral Surgery and Transplantation Inselspital Bern 3010 Bern	OCS 01431-08-2003 Systemic Gene Therapy of Hepatocellular Carcinoma by tumortargeted, self-limited E2F-1 Overexpression from the human Telomerase Reverse Transcriptase (hTERT) Promoter	12	74'600
Ziemiecki Andrew , Prof. Dr. Tiefenau Labor Departement Klinische Forschung 3004 Bern	OCS 01510-02-2004 Transgenic mouse models to study the molecular mechanism(s) leading to the invasive phenotype of mammary tumors	24	212'700
Zuppinger Christian , Dr. sc. nat. Inselspital Bern 3010 Bern	OCS 01582-08-2004 Targeted cancer therapy and the heart: Mechanisms of carditoxicity caused by the modulation of the erbB2/HER2 signalling axis in the adult myocardium and in isolated cardiomyocytes	24	92'000

Collaborative Cancer Research Projects

<p>Bertoni Francesco Dr. Oncology Institute Southern Switzerland 6500 Bellinzona</p> <p>Together with: Aguzzi Adriano, Prof. Dr. med. Universitätsspital Departement Pathologie 8091 Zürich Zucca Emanuele, Prof. Dr. IOSI-Medical Oncology Dept. Ospedale San Giovanni 6500 Bellinzona Uguccione Mariagrazia, Dr. Institute for Research in Biomedicine (IRB) 6500 Bellinzona Heppner Frank. L., Dr. Institute of Neuropathology (NPZ) 8091 Zürich Ponzoni Maurilio, Dr. Department of Pathology Ospedale S. Raffaele (HSR) IT-20100 Milano Ferreri Andres J., Dr. Department of Radio- Chemotherapy Ospedale S. Raffaele (HSR) IT-20100 Milano Zaffalon Marco, Dr. Istituto Dalle Molle di Studi sull'Intelligenza Artificiale (IDSIA) 6928 Manno Bicciato Silvio, Dr. Dip. Processi Chimici dell'Ingegneria Univerista' di Padova (UPD) IT-35131 Padova Mazzucchelli Luca, Dr. Istituto Cantonale di Patologia (ICPL) 6601 Locarno</p>	<p>KFP OCS 01443-12-2003 Primary central nervous system lymphoma: from an improved knowledge of its peculiar molecular and biologic feature towards the optimization of treatment</p>	<p>24</p>	<p>450'000</p>
<p>Briskin Cathrin, Dr Swiss Institute for Experimental Cancer Research ISREC 1066 Epalinges</p> <p>Together with: Hynes Nancy, Prof. Dr. Friedrich Miescher-Institut 4058 Basel Fiche Maryse, Dr. Institut Universitaire de Pathologie, CHUV 1011 Lausanne</p>	<p>KFP OCS 01445-12-2003 The role of Wnt signaling in breast cancer</p>	<p>36</p>	<p>1'050'000</p>

Stipendiengesuche

Bourses de recherche

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
<i>Candidat/e</i>	<i>Numero du projet Titre du projet</i>	<i>Durée (mois)</i>	<i>Montant (CHF)</i>
Gautschi Oliver , Dr. med. 3097 Liebefeld Destination: Davis Cancer Center, University of California USA - Sacramento	BIL OCS 01599-08-2004 Die Rolle der beim Lungenkrebs überexprimierten, mitotischen Kinasen	18	35'300
Jandus Camilla 1010 Lausanne	MD-PhD 01549-05-2004 SAMW MD-PhD Stipendium	36	150'000
Lannen Patricia 3013 Bern Destination: Center of Mindfulness Worcester University Amherst USA - Massachusetts	BIL OCS 01598-08-2004 Aufmerksamkeitslenkung und persönliche Reife als wichtige Therapieaspekte in der Psychoonkologie	6	19'800
Novak Urban , Dr. med 3010 Bern Destination: Institute for Cancer Genetics Columbia University USA - New York, NY 10032	BIL KLS 01522-02-2004 Rolle der Activation-Induced Deaminase (AID) und der aberranten Hypermutation bei Non-Hodgkin-Lymphomen	12	59'000
Pebernard Stephanie , Dr. 1066 Epalinges Destination: The Scripps Research Institute USA - La Jolla, CA 92037	BIL KLS 01525-02-2004 Characterization of the Cds1-Rad60 pathway	24	76'526
Schüpbach Jonas , Dr. med. 3010 Bern Destination: Centre Antoine- Lacassagne Centre Hospitalier Universitaire de Nice F- 06189 Nice	BIL KLS 01526-02-2004 Microvascular dynamics of free flaps in Head and Neck Surgery	10	38'000
Shaha Maya , Dr. 5034 Suhr Destination: John Hopkins University USA- Baltimore, Maryland 21205	BIL OCS 01532-03-2004 Psycho-oncological issues in cancer care	24	86'400
Stern Martin , Dr. med. 4052 Basel Destination: Perugia University School of Medicine IT- 06122 Perugia	BIL OCS 01597-08-2004 Ausnützung der Allo-Reaktivität von Natural- Killer-Lymphocyten bei der haplo-identischen Stammzelltransplantation	24	76'000